Eur Rev Med Pharmacol Sci 2022; 26 (20): 7482-7492
DOI: 10.26355/eurrev_202210_30018

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

N. Ferri, A. Corsini, R. Pontremoli

Department of Medicine, University of Padua, Padua, Italy. nicola.ferri@unipd.it


OBJECTIVE: The aim of the study was to review the literature on clinical pharmacology of lercanidipine and experimental and clinical evidence and evaluate its ability to reduce proteinuria and preserve renal function when used as monotherapy or in combination with the angiotensin-converting enzyme (ACE) inhibitor enalapril.

MATERIALS AND METHODS: MEDLINE/PubMed was searched for appropriate keywords.

RESULTS: Lercanidipine, a third-generation calcium channel blocker, has been shown to have a unique pharmacological and clinical profile, which translates into favorable renal hemodynamic changes. The fixed-dose combination lercanidipine/enalapril has been proposed to overcome unmet therapeutic needs, often as the initial treatment in the high-risk patient.

CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.

Free PDF Download

To cite this article

N. Ferri, A. Corsini, R. Pontremoli
Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 20
Pages: 7482-7492
DOI: 10.26355/eurrev_202210_30018